肠杆菌科菌血症短疗程与长疗程抗生素治疗的多中心倾向评分匹配队列比较
该多中心回顾性队列纳入2008–2014年单种肠杆菌科菌血症且接受体外有效治疗6–16天的成人患者,经1:1倾向评分匹配后比较短疗程(6–10天)与长疗程(11–16天)的结局。
要点
- 肠杆菌科菌血症短疗程(6–10天)与长疗程(11–16天)30天全因死亡率无差异。
- 两组复发血流感染与艰难梭菌感染风险相似。
- 短疗程对后续多重耐药革兰阴性菌出现呈保护趋势但未达统计学显著。
核心结论
- 肠杆菌科菌血症短疗程抗生素治疗与长疗程临床结局相似,且可能减少后续MDRGN细菌出现。
研究设计与样本
- 3个医疗中心回顾性队列,纳入2008–2014年单种肠杆菌科菌血症且接受体外有效治疗6–16天的患者。
- 采用1:1最近邻倾向评分匹配(无放回)后行回归分析,共385对匹配患者。
主要发现
- 短疗程组中位治疗8天(IQR 7–9天),长疗程组15天(IQR 13–15天)。
- 复发血流感染与CDI的比值相似。
临床怎么用
- 对体外有效治疗的肠杆菌科菌血症成人,可考虑短疗程(6–10天)抗生素治疗。
- 短疗程可能有助于减少后续多重耐药革兰阴性菌出现。
局限性
- 为回顾性队列研究,尽管采用倾向评分匹配,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recommended duration of antibiotic treatment for Enterobacteriaceae bloodstream infections is 7-14 days. We compared the outcomes of patients receiving short-course (6-10 days) vs prolonged-course (11-16 days) antibiotic therapy for Enterobacteriaceae bacteremia. METHODS: A retrospective cohort study was conducted at 3 medical centers and included patients with monomicrobial Enterobacteriaceae bacteremia treated with in vitro active therapy in the range of 6-16 days between 2008 and 2014. 1:1 nearest neighbor propensity score matching without replacement was performed prior to regression analysis to estimate the risk of all-cause mortality within 30 days after the end of antibiotic treatment comparing patients in the 2 treatment groups. Secondary outcomes included recurrent bloodstream infections, Clostridium difficile infections (CDI), and the emergence of multidrug-resistant gram-negative (MDRGN) bacteria, all within 30 days after the end of antibiotic therapy. RESULTS: There were 385 well-balanced matched pairs. The median duration of therapy in the short-course group and prolonged-course group was 8 days (interquartile range [IQR], 7-9 days) and 15 days (IQR, 13-15 days), respectively. No difference in mortality between the treatment groups was observed (adjusted hazard ratio [aHR], 1.00; 95% confidence interval [CI], .62-1.63). The odds of recurrent bloodstream infections and CDI were also similar. There was a trend toward a protective effect of short-course antibiotic therapy on the emergence of MDRGN bacteria (odds ratio, 0.59; 95% CI, .32-1.09; P = .09). CONCLUSIONS: Short courses of antibiotic therapy yield similar clinical outcomes as prolonged courses of antibiotic therapy for Enterobacteriaceae bacteremia, and may protect against subsequent MDRGN bacteria.
引用
- Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis. 2018. PMID: 29190320. doi:10.1093/cid/cix767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。